LUMAKRAS^® (Sotorasib) Receives Approval in Japan for Patients with KRAS G12C-Mutated Advanced Non-small Cell Lung Cancer

Amgen announced that LUMAKRAS^® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer that has progressed after systemic anticancer therapy.